Annovis Bio (ANVS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
11 Sep, 2026Executive summary
Special Meeting scheduled for October 14, 2026, to be held virtually for all shareholders of record as of September 4, 2026.
Three main proposals: increase in authorized shares, ratification of equity plan amendment, and potential adjournment to solicit more proxies.
Board of Directors unanimously recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposal 1: Amend Certificate of Incorporation to increase authorized Common Stock from 70M to 140M and Preferred Stock from 2M to 10M.
Proposal 2: Ratify amendment to the 2019 Equity Incentive Plan, correcting a prior typographical error and increasing the share reserve to 5.5M shares.
Proposal 3: Approve adjournment of the meeting if more time is needed to solicit proxies.
Board recommends a vote "FOR" all proposals.
Shareholders must provide explicit voting instructions for Proposals 1 and 2; otherwise, shares will not be voted on these matters.
Board of directors and corporate governance
Directors and executive officers collectively own approximately 15.92% of outstanding common stock.
No special benefits to directors or officers from the proposals, except potential participation in the Option Plan.
Procedures for shareholder proposals and director nominations for the 2027 Annual Meeting are outlined, with specific deadlines.
Latest events from Annovis Bio
- Alzheimer's phase III top-line data due in March; funding needed to reach NDA and commercialization.ANVS
Investor update - Shareholders will vote on increasing authorized shares and ratifying an equity plan amendment.ANVS
Proxy filing - Net loss rose sharply as clinical trial costs surged, with cash runway only through Q4 2026.ANVS
Q2 2026 - Buntanetap shows late-stage efficacy and safety in Alzheimer's and Parkinson's, targeting NDA filings in 2027–2028.ANVS
Investor presentation - Buntanetap delivers cognitive and motor improvements in AD and PD with strong safety and biomarker support.ANVS
Corporate presentation - Q1 net loss rose to $17.6M as R&D spending surged; cash runway extends to Q4 2026.ANVS
Q1 2026 - Virtual annual meeting set for June 17, 2026, with key votes on directors and compensation.ANVS
Proxy filing - Annual meeting to vote on directors, auditor, equity plan, executive pay, and ESG priorities.ANVS
Proxy filing - Buntanetap delivers cognitive and motor benefits in AD and PD, with strong safety and market potential.ANVS
Corporate presentation